Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX01 in CIPN (ACT)
NCT05593614Phase 2Active, not recruiting
- Sponsor
- AlgoTherapeutix
- Start
- Feb 2023
- Primary completion
- Sep 2024
- Modality
- Gene Editing, Gene Silencing, Modified DNA Oligonucleotides
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of ATX-01 in chemotherapy-induced peripheral neuropathy (CIPN) (3 arms), sponsored by AlgoTherapeutix. Primary endpoint: Change from baseline to Week 12 in the weekly mean of the daily NPRS score assessing average pain intensity in target study extremities related to CIPN in the past 24 hours. Started Feb 2023; status: active, not recruiting.
02
Drugs
ATX-01
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05593614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05593614.